Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands

OBJECTIVE: Choosing therapies for type 2 diabetes that are both effective and cost-effective is vital as healthcare systems worldwide aim to maximize health of the population. The present analysis assessed the cost-effectiveness of once-weekly semaglutide (a novel glucagon-like peptide-1 (GLP-1) rec...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMJ Open Diabetes Res Care
Main Authors: Hunt, Barnaby, Malkin, Samuel J P, Moes, Robert G J, Huisman, Eline L, Vandebrouck, Tom, Wolffenbuttel, Bruce H R
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2019
Assuntos:
Emerging Technologies, Pharmacology and Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6777406/
https://ncbi.nlm.nih.gov/pubmed/31641522
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjdrc-2019-000705
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados